290 related articles for article (PubMed ID: 10090437)
21. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
Bradford WD; Kleit AN; Nietert PJ; Ornstein S
Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
[TBL] [Abstract][Full Text] [Related]
22. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Simpson RJ; Signorovitch J; Ramakrishnan K; Ivanova J; Birnbaum H; Kuznik A
Am J Ther; 2011 Nov; 18(6):436-48. PubMed ID: 20802306
[TBL] [Abstract][Full Text] [Related]
24. [Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Marta-Moreno J; Echeandia C; Oliveros-Cid A; Figuerola A; Mola S
Rev Neurol; 1998 Nov; 27(159):827-30. PubMed ID: 9859160
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of three statins at lower maintenance doses.
Carr-Lopez S; Exstrum T; Morse T; Shepherd M; Bush AC
Clin Ther; 1999 Feb; 21(2):331-9. PubMed ID: 10211536
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats.
Bezerra DG; Mandarim-de-Lacerda CA
Clin Sci (Lond); 2005 Apr; 108(4):349-55. PubMed ID: 15610072
[TBL] [Abstract][Full Text] [Related]
27. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
Eckernäs SA; Roos BE; Kvidal P; Eriksson LO; Block GA; Neafus RP; Haigh JR
Br J Clin Pharmacol; 1993 Mar; 35(3):284-9. PubMed ID: 8471404
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
29. Is there a relationship between early statin compliance and a reduction in healthcare utilization?
Aubert RE; Yao J; Xia F; Garavaglia SB
Am J Manag Care; 2010 Jun; 16(6):459-66. PubMed ID: 20560689
[TBL] [Abstract][Full Text] [Related]
30. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
31. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; Vyas KP; Kari PH; MacDonald JS
J Pharmacol Exp Ther; 1991 Jun; 257(3):1225-35. PubMed ID: 1904494
[TBL] [Abstract][Full Text] [Related]
32. The use over time of statins in coronary patients in an Italian tertiary referral center.
Gaspardone A; Proietti I; Altamura L; Tomai F; Versaci F; Crea F; Chiariello L; Gioffrè PA
Ital Heart J; 2001 Nov; 2(11):848-53. PubMed ID: 11770871
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of statins.
Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
[TBL] [Abstract][Full Text] [Related]
34. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
[TBL] [Abstract][Full Text] [Related]
35. The risk for significant creatine kinase elevation with statins.
Stolcpart RS; Olson KL; Delate T; Rasmussen J; Rehring TF; Merenich JA
Am J Cardiovasc Drugs; 2010; 10(3):187-92. PubMed ID: 20524720
[TBL] [Abstract][Full Text] [Related]
36. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF
Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499
[TBL] [Abstract][Full Text] [Related]
37. Pravastatin versus simvastatin for prevention of contrast-induced nephropathy.
Muñoz MA; Maxwell PR; Green K; Hughes DW; Talbert RL
J Cardiovasc Pharmacol Ther; 2011; 16(3-4):376-9. PubMed ID: 21386035
[TBL] [Abstract][Full Text] [Related]
38. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
Schmidt J; Schmitt C; Hockwin O
Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
[TBL] [Abstract][Full Text] [Related]
39. Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?
Hickman J
Br J Gen Pract; 2010 Jan; 60(570):50-2. PubMed ID: 20040169
[TBL] [Abstract][Full Text] [Related]
40. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
